To our esteemed colleagues around the globe: The COVID-19 pandemic is going to get worse before it gets better, so the medical statistics demonstrate. At this point, it has already required us to adapt to social distancing and caused us all to reevaluate how we work...
Amplion’s Machine Learning Platform Accelerates Precision Medicine Collaboration Dx:Revenue™ solution rapidly identifies and qualifies drug and test developer partnership opportunities Effective partnerships between pharmaceutical companies, biotechs, academia,...
Seattle’s annual GeekWire Summit brings together thousands of tech and business leaders for a conversation about the future. This year, organizers are hosting a panel discussion on The Quest for Personalized Medicine that will include Dr. Amanda Enstrom, Amplion’s...
Biomarker Intelligence company to aggressively accelerate sales, marketing and execution of product roadmap Amplion, an Oregon-based Biomarker Intelligence company, announced the successful close of its Series A financing led by Greycroft with participation from...
Recent research on clinical trial success rates that caught our eye: We are especially encouraged to see a group from MIT carrying forward the torch of drug likelihood-of-approval (LOA) analysis. That group of researchers put together this great analysis of what they...
We have been working with Bio-Rad. As most of you know Bio-Rad provides the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. They are...
We announced our new literature-focused features in our last blog post. One of the unique features of our approach is that we use deep learning concepts, a subset of machine learning, to text mine literature. A characteristic of deep learning is that various...
We are excited to announce improvements to BiomarkerBase, increasing the coverage and analysis of literature. We’ve added biomarkers sourced only from literature, representing biomarkers in an earlier stage of development. With this addition there are two main...
When building a company, especially a startup, you look forward to moments that change your trajectory. So, when Mary Meeker included our analysis in her annual Internet trends presentation, it got us thinking. For those of you that don’t know, Mary Meeker is a...
What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how...
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
